Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up

Y Fradet; J Bellmunt; DJ Vaughn; JL Lee; L Fong; NJ Vogelzang; MA Climent; DP Petrylak; TK Choueiri; A Necchi; W Gerritsen; H Gurney; DI Quinn; S Culine; CN Sternberg; K Nam; TL Frenkl; RF Perini; Ronald de Wit; DF Bajorin

doi:10.1093/annonc/mdz127

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up

Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, MA Climent, DP Petrylak, TK Choueiri, A Necchi, W Gerritsen, H Gurney, DI Quinn, S Culine, CN Sternberg, K Nam, TL Frenkl, RF Perini, Ronald de Wit, DF Bajorin

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

229 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	970-976
Number of pages	7
Journal	Annals of Oncology
Volume	30
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdz127
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz127

http://hdl.handle.net/1765/119481

Cite this

Fradet, Y., Bellmunt, J., Vaughn, DJ., Lee, JL., Fong, L., Vogelzang, NJ., Climent, MA., Petrylak, DP., Choueiri, TK., Necchi, A., Gerritsen, W., Gurney, H., Quinn, DI., Culine, S., Sternberg, CN., Nam, K., Frenkl, TL., Perini, RF., de Wit, R., & Bajorin, DF. (2019). Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Annals of Oncology, 30(6), 970-976. https://doi.org/10.1093/annonc/mdz127

@article{3d55209df7eb44ad8770faa42972e37a,

title = "Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up",

author = "Y Fradet and J Bellmunt and DJ Vaughn and JL Lee and L Fong and NJ Vogelzang and MA Climent and DP Petrylak and TK Choueiri and A Necchi and W Gerritsen and H Gurney and DI Quinn and S Culine and CN Sternberg and K Nam and TL Frenkl and RF Perini and {de Wit}, Ronald and DF Bajorin",

year = "2019",

doi = "10.1093/annonc/mdz127",

language = "Undefined/Unknown",

volume = "30",

pages = "970--976",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "6",

}

Fradet, Y, Bellmunt, J, Vaughn, DJ, Lee, JL, Fong, L, Vogelzang, NJ, Climent, MA, Petrylak, DP, Choueiri, TK, Necchi, A, Gerritsen, W, Gurney, H, Quinn, DI, Culine, S, Sternberg, CN, Nam, K, Frenkl, TL, Perini, RF, de Wit, R & Bajorin, DF 2019, 'Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up', Annals of Oncology, vol. 30, no. 6, pp. 970-976. https://doi.org/10.1093/annonc/mdz127

TY - JOUR

T1 - Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up

AU - Fradet, Y

AU - Bellmunt, J

AU - Vaughn, DJ

AU - Lee, JL

AU - Fong, L

AU - Vogelzang, NJ

AU - Climent, MA

AU - Petrylak, DP

AU - Choueiri, TK

AU - Necchi, A

AU - Gerritsen, W

AU - Gurney, H

AU - Quinn, DI

AU - Culine, S

AU - Sternberg, CN

AU - Nam, K

AU - Frenkl, TL

AU - Perini, RF

AU - de Wit, Ronald

AU - Bajorin, DF

PY - 2019

Y1 - 2019

U2 - 10.1093/annonc/mdz127

DO - 10.1093/annonc/mdz127

M3 - Article

SN - 0923-7534

VL - 30

SP - 970

EP - 976

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -